5 Analysts Have This to Say About Pacific Biosciences
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has received mixed ratings from analysts in the last quarter, with one bullish rating and four indifferent ratings. The average 12-month price target for the company has increased by 13.6% from the previous average of $12.50 to $14.2, according to five analysts.
September 26, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and an increased average 12-month price target could lead to uncertainty in the short term for Pacific Biosciences.
The mixed analyst ratings indicate uncertainty about the company's performance. While the increased average 12-month price target suggests some analysts are optimistic about the company's future, the majority of ratings are indifferent, which could lead to uncertainty in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100